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A B S T R A C T
Purpose
Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL)
requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified.
Patients and Methods
We conducted an open-label, multicenter, randomized trial among adult patients with previously
untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles
of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone
(FM). The principal end point of the study was time to treatment failure (TTF).
Results
There were 534 patients enrolled onto the study. Overall response rates were 88%, 93%, and
91% for R-CVP, R-CHOP, and R-FM, respectively (P  .247). After a median follow-up of 34
months, 3-year TTFs were 46%, 62%, and 59% for the respective treatment groups (R-CHOP
v R-CVP, P  .003; R-FM v R-CVP, P  .006; R-FM v R-CHOP, P  .763). Three-year
progression-free survival (PFS) rates were 52%, 68%, and 63% (overall P  .011), respec-
tively, and 3-year overall survival was 95% for the whole series. R-FM resulted in higher rates
of grade 3 to 4 neutropenia (64%) compared with R-CVP (28%) and R-CHOP (50%; P  .001).
Overall, 23 second malignancies were registered during follow-up: four in R-CVP, five in
R-CHOP, and 14 in R-FM.
Conclusion
In this study, R-CHOP and R-FM were superior to R-CVP in terms of 3-year TTF and PFS. In
addition, R-CHOP had a better risk-benefit ratio compared with R-FM.
J Clin Oncol 31:1506-1513. © 2013 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma (FL) is the most frequent in-
dolent lymphoma subtype, accounting for 10% to
20% of all non-Hodgkin lymphomas in Western
countries. At time of diagnosis, most patients have
advanced disease, which requires systemic treat-
ment. Although effective therapies are available, pa-
tients with FL still experience frequent relapses and
shorter remissions at every disease recurrence. Re-
cently, the outcome of FL has consistently im-
proved, mainly as a result of the adoption of effective
induction and salvage therapies.1
The current standard treatment for advanced
FL includes immunochemotherapy (ICT), a combi-
nation of multiagent chemotherapy with anti-CD20
monoclonal antibody rituximab (R). Compared
with chemotherapy alone, ICT has been associated
with higher response, progression-free survival
(PFS), and overall survival (OS) rates.2-5 Although
the addition of R to chemotherapy is supported with
the highest levels of evidence, less is known about
which chemotherapy regimen should be chosen to
achieve better results.
Several chemotherapy regimens have been ad-
opted for the initial treatment of FL, ranging from
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single- to multiagent chemotherapies with or without anthracy-
clines.6,7 More recently, purine analogs have also been proposed.8-10
At present, the choice of initial therapy is still a matter of debate, with
the anthracycline-containing regimen of cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (CHOP) being the most widely
adopted so far.5,11,12
In 2006, the Fondazione Italiana Linfomi (formerly Intergruppo
Italiano Linfomi) started a large prospective, randomized, multicenter
trial to identify the best chemotherapy regimen to combine with R for
first-line treatment of advanced FL. The study compared rituximab
plus cyclophosphamide, vincristine, and prednisone (R-CVP) with
R-CHOP and rituximab plus fludarabine and mitoxantrone (R-FM)
ICT regimens. Here we describe the final results of the study, which
completed accrual in September 2010.
PATIENTS AND METHODS
The study was performed as a prospective, randomized, open-label, multi-
center phase III trial. It was conducted in compliance with the Declaration of
Helsinki, was approved by the appropriate research ethics committee, and
required each patient to provide written informed consent before registration
and random assignment.
The trial included previously untreated patients age 18 to 75 years, with
histologically confirmed diagnosis of grade 1, 2, or 3a FL according to WHO
classification,13 Ann Arbor stage II to IV disease, Eastern Cooperative Oncol-
ogy Group performance status of 0 to 2, and active disease according to the
Italian Society of Hematology guidelines.14 Patients ineligible for enrollment
included those with grade 3b FL, Ann Arbor stage I disease, evidence of
histologic transformation to diffuse large B-cell lymphoma, CNS involvement,
or history of severe cardiac disease or previous malignancy other than in situ
carcinoma of the cervix or basal cell carcinoma of the skin. Exclusion criteria
also encompassed renal or hepatic function impairment not caused by lym-
phoma, known HIV infection, and hepatitis B (hepatitis B surface antigen
positive) or C. Pregnant or lactating women and potentially childbearing
women not using a reliable method of contraception were also excluded.
Central pathology review was performed for all patients with grade 3
FL or when grading was not specified in the local pathology report. For all
other patients, no review was performed, and local diagnosis was accepted.
Initial diagnostic and staging workup included physical examination;
computed tomography (CT) scan with iodine contrast of the neck, chest,
and abdomen; bone marrow (BM) biopsy; and complete set of laboratory
tests. Positron emission tomography scan was not used for stage definition
or response assessment.
Random Assignment and Treatment Protocol
Before registration, all patients signed an informed consent form. Eligible
patients were randomly assigned according to a central procedure stratified by
Follicular Lymphoma International Prognostic Index (FLIPI) score (0 to 2 v 3
to 5).15
The three study arms included eight doses of R combined with eight
courses of CVP (control arm) or six cycles of CHOP or six cycles of FM, every
3 weeks. Drug doses and administration schedules for each regimen are sum-
marized in Table 1. Growth factors were not routinely administered. Interme-
diate and final response assessments were required after cycle three and within
1 month after last R infusion, respectively. Patients showing progressive (PD)
or stable disease (SD) were coded as experiencing treatment failure and shifted
to salvage treatment at physicians’ discretion. According to study protocol,
maintenance therapy was not permitted.
Response assessment was to be performed with physical examination,
laboratory tests, and total-body CT scan with contrast medium; BM biopsy
was required only for assessment of final response if positive at baseline.
During follow-up, disease status was to be assessed at months3,6,12,
18,24, and36 with CT scan and with BM biopsy if positive at baseline.
Statistics and Assessment of Efficacy
Time to treatment failure (TTF) was the primary end point of the study,
defined as time from date of study entry to last follow-up or to the first of the
following events: less than partial remission (PR), shift to a different therapy
for any reason after at least cycle one, PD or relapse, or death. Additional study
end points were PFS, OS, response rate, and toxicity. PFS was measured from
date of study entry to last follow-up or to one of the following events: PD,
relapse, or death resulting from any cause. OS was defined from date of study
entry to date of last observation or death resulting from any cause.
Response was assessed according to international criteria.16 Patients with
negative baseline BM biopsy were classified as experiencing complete remis-
sion (CR) based on CT scan results, even if BM biopsy was not repeated at end
of treatment. Toxicity was measured according to the standard Common
Toxicity Criteria for Adverse Events (version 3.0; http://ctep.cancer.gov/
reporting/ctc.html) on a patient basis. The delivered dose-intensity was calcu-
lated according to Hryniuk,17 taking into account R as well.
The sample size was initially calculated at 252 patients according to the
primary study end point (TTF) with the following initial assumptions: two-
sided 5% significance test ( error, 0.05) with a three-arm trial; power of 80%
(error, 0.2) with 3 years of uniform recruitment and 2 years of follow-up; and
hazard ratio (HR) of 0.53 for TTF in the experimental arms, assuming median
TTF of 32 months for R-CVP as reference.2 After enrollment of the first 214
patients, because actual accrual was faster than expected, the study was
amended as follows: 4 years of uniform recruitment, 1 year of follow-up from
last enrolled patient, and final accrual of 534 patients (178 patients per study
arm). This allowed us to perform multiple comparisons among study arms,
with a two-sided type I error controlled by the Bonferroni correction (0.05/
3),18 type II error of 0.10 (90% power), and 5% dropout rate. The initial
hypothesis of an HR of 0.53 would be then realized with 200 events; with the
hypothesis of an HR of 0.6, 211 events would have been required to achieve a
test power of 84%. An interim analysis of TTF was planned at 20%, 34%, 50%,
and 70% of the required events (approximately 200 events). To control the
overall type I error, the Lan-DeMets alpha-spending function was used with
O’Brien-Fleming boundaries of 0.0001, 0.0001, 0.0011, and 0.0042 at the
interim analysis and 0.0115 at the final analysis for the two pairwise compari-
sons of R-CHOP versus R-CVP and R-FM versus R-CVP.
Table 1. Drug Doses and Time Schedules of the Three
Chemotherapy Regimens
Drug Dose (mg/m2) Route Days
R-CVP
Cyclophosphamide 750 IV 1
Vincristine 1.4† IV 1
Prednisone 40 PO 1-5
Rituximab 375 IV 1
R-CHOP
Cyclophosphamide 750 IV 1
Doxorubicin 50 IV 1
Vincristine 1.4† IV 1
Prednisone 100 PO 1-5
Rituximab 375 IV 1
R-FM
Fludarabine 25 IV 1-3
Mitoxantrone 10 IV 1
Rituximab 375 IV 1
NOTE. Eight courses of R-CVP and six courses of R-CHOP and R-FM were
administered. For R-FM and R-CHOP, two additional courses (every 21 days)
of rituximab were scheduled.
Abbreviations: IV, intravenously; PO, orally; R-CHOP, rituximab plus cyclo-
phosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus
cyclophosphamide, vincristine, and prednisone; R-FM, rituximab plus fludara-
bine and mitoxantrone.
Every 21 days.
†Capped at a total dose of 2 mg.
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Study end points were evaluated according to the intention-to-treat
principle, with the provision that patients for whom exclusion criteria were
discovered after random assignment or who withdrew their consent would be
excluded from analysis.19 In the TTF analysis, the reported P values in tables
and figures were not adjusted for multiple comparisons. HRs for TTF and PFS
were adjusted using FLIPI.
All statistical analyses were performed using STATA statistical software
(release 10.1; College Station, TX). Survival curves were calculated using
Kaplan-Meier estimates,20 and statistical comparisons between curves were
made using the log-rank test. Post hoc comparisons between TTF and PFS,
adjusted by potentially confounding factors, were performed using the Cox
proportional hazards regression method.21 Proportionality of hazard was
checked graphically by means of scaled Schoenfeld residuals.22 The2, Fisher’s
exact, and Kruskal-Wallis tests were used to compare variables when appro-
priate.23 All statistical comparisons were two sided.
RESULTS
Between March 2006 and September 2010, 534 patients were enrolled
onto the FOLL05 trial by 58 Italian institutions, with 178 patients in
each study arm. Thirty patients (6%) were subsequently excluded
(unconfirmed histology, 17; consent withdrawal, eight; synchronous
cancer, four; HIV positivity, one), and the remaining 504 patients
were analyzed (Fig 1). As shown in Table 2, patients were homoge-
neously distributed.
Planned interim analyses performed during the enrollment pe-
riod allowed continuation of the trial. Median overall delivered dose-
intensities were 0.956, 0.964, and 0.918 for R-CVP, R-CHOP, and
R-FM, respectively. Response was available for 501 patients.
At the end of induction therapy, the three arms (R-CVP,
R-CHOP, and R-FM) had similar CR rates: 67% (95% CI, 60% to
74%), 73% (95% CI, 65% to 78%), and 72% (95% CI, 65% to 78%),
respectively (P  .543); overall response rates (ORRs; CR plus PR)
were 88% (95% CI, 82% to 93%), 93% (95% CI, 88% to 97%), and
91% (95% CI, 86% to 95%), respectively (P  .247). After median
follow-up of 34 months (range, 1 to 70 months), 213 failures were
recorded, as summarized in Table 3. Overall 3-year TTF was 56%.
In terms of TTF, R-CHOP and R-FM were significantly better
than R-CVP (62% and 59% v 46% at 3-years; P  .003 and .006,
respectively; Fig 2A). No differences were observed between R-CHOP
and R-FM (P  .763). HRs between R-CHOP versus R-CVP and
R-FM versus R-CVP, adjusted by FLIPI (0 to 2 v 3-5), were 0.62 (95%
CI, 0.44 to 0.86) and 0.63 (95% CI, 0.46 to 0.87), respectively.
Overall, 184 patients developed PD, including 13 PD during
therapy, 11 PD from SD, 152 relapses or progressions from CR or PR,
and eight deaths in CR or PR, thus resulting in a 3-year PFS of 61%.
Better PFS rates were observed for R-CHOP and R-FM over R-CVP
(68% and 63% v 52% at 3 years), with adjusted HRs for R-CHOP
versus R-CVP and R-FM versus R-CVP of 0.64 (95% CI, 0.45 to 0.92)
and 0.66 (95% CI, 0.47 to 0.94), respectively (Fig 2B).
At final follow-up, 31 deaths were recorded. Because the study
was not powered for OS analysis, no comparison among study arms
was performed. Lymphoma-related deaths included PD or recurrence
(n 19); other causes of death were secondary malignancy (n 5),
heart failure (n  3), infection (n  2), cachexia nonlymphoma
related (n 1), and car accident (n 1). OS at 3 years was 95% (95%
CI, 92% to 97%).
Study regimens were generally well tolerated. Patients treated
with R-FM had the highest rate of grade 3 to 4 neutropenia, followed
by those receiving R-CHOP and R-CVP (64% v 50% and 28%).
Frequency of grade 3 to 4 thrombocytopenia was higher with
R-CHOP and R-FM (3% and 8%) than with R-CVP (0%; P .001).
Overall, grade 3 to 4 infections occurred in 17 patients at a rate of 2.4%,
3%, and 4.7% for R-CVP, R-CHOP and R-FM, respectively (P .527;
Appendix Table A1, online only). Granulocyte colony-stimulating
factor was used at least once during therapy in 46% of patients: 30% in
Patients recruited
(N = 534)
Random assignment stratified by FLIPI (0-2 v 3-5)
Excluded (n = 10)
  Revised histology (n = 2)
    MZL (n = 1)
    MCL (n = 1)
  Concomitant neoplasia (n = 3)
    Kidney (n = 1)
    Lung (n = 1)
    AML (n = 1)
  Consent withdrawal (n = 5)
Excluded (n = 13)
  Revised histology (n = 10)
    DLBCL (n = 4)
    FL+DLBCL (n = 3)
    MCL (n = 3)
  HIV+ (n = 1)
  Consent withdrawal (n = 2)
Excluded (n = 7)
  Revised histology (n = 5)
    DLBCL (n = 5)
  Concomitant neoplasia (n = 1)
    Lung (n = 1)
  Consent withdrawal (n = 1)
Eligible for ITT analysis (n = 168)
  Full course (n = 148)
  Partial course (n = 19)
  Lost before response (n = 1)
Eligible for ITT analysis (n = 165)
  Full course (n = 158)
  Partial course (n = 6)
  Lost before response (n = 1)
Eligible for ITT analysis (n = 171)
  Full course (n = 161)
  Partial course (n = 9)







Fig 1. Treatment allocation and number of
patients included in analysis, according to
the CONSORT statement.19 After random
assignment, 30 patients were considered
ineligible and were subsequently excluded.
AML, acute myeloid leukemia; DLBCL, dif-
fuse large B-cell lymphoma; FL, follicular
lymphoma; FLIPI, Follicular Lymphoma In-
ternational Prognostic Index; ITT, intention
to treat; MCL, mantle cell lymphoma; MZL,
marginal zone lymphoma; R-CHOP, ritux-
imab plus cyclophosphamide, doxorubicin,
vincristine, and prednisone; R-CVP, ritux-
imab plus cyclophosphamide, vincristine,
and prednisone; R-FM, rituximab plus flu-
darabine and mitoxantrone.
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R-CVP, 52% in R-CHOP, and 57% in R-FM arms, respectively (P
.001). Nonhematologic toxicity was similar in all three arms, with a
marginal excess of neurotoxicity in R-CVP; cardiac events were re-
ported in five patients and were graded 3 to 4 in two (one each for
R-CVP and R-CHOP). There were no treatment-related deaths.
During follow-up, 23 patients were diagnosed with a second malig-
nancy: four in R-CVP (one colon cancer, one prostate cancer, one Kapo-
si’s sarcoma, and one breast cancer), five in R-CHOP (three lung cancers,
one glioblastoma, and one endometrial cancer), and 14 in R-FM (three
acute myeloid leukemias, one chronic myelomonocytic leukemia, two
squamous cell skin cancers, one cervical cancer, one uterine cancer, one
colon cancer, one prostate cancer, one lung cancer, one Warthin’s cancer,
one breast cancer, and one Hodgkin lymphoma).
We performed a post hoc exploratory analysis of patient sub-
groups categorized by age, hemoglobin level, size of largest involved
node, 2-microglobulin, BM involvement, and FLIPI (Figs 3A and
Table 2. Patient Demographic and Clinical Characteristics by Treatment Arm
Characteristic
R-CVP (n  168) R-CHOP (n  165) R-FM (n  171)
No. % No. % No. %
Age, years (range)
Median 56 56 54
Range 31-75 33-75 30-75
 60 53 32 56 34 58 34
Male sex 87 52 83 50 94 55
Histotype, grade
1 53 32 63 38 51 30
2 77 46 59 36 90 53
3a 21 12 26 16 21 12
Unclassified 17 10 17 10 9 5
Ann Arbor stage
II 14 8 17 10 12 7
III 57 34 42 26 46 27
IV 97 58 106 64 113 66
ECOG performance status  1 5 3 5 3 4 2
FLIPI
0-2 105 62 106 64 105 61
3-5 63 38 59 36 66 39
FLIPI2
0 31 18 32 19 24 14
1-2 100 60 88 53 94 55
3-5 37 22 45 27 53 31
Serum 2-microglobulin  UNL 70 42 73 44 81 47
Bone marrow involvement 85 51 89 54 100 58
LoDLIN  6 cm 44 26 39 24 51 30
Hemoglobin  12 g/dL 25 15 28 17 27 16
Median delivered dose-intensity 0.96 0.96 0.92
NOTE. Because of rounding, percentages may not total 100.
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LoDLIN, longest diameter of largest
involved node; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab plus cyclophosphamide, vincristine, and
prednisone; R-FM, rituximab plus fludarabine and mitoxantrone; UNL, upper normal limit.
Table 3. TTF Distribution by Treatment Arm
Status
R-CVP R-CHOP R-FM Total
No. % No. % No. % No. %
Censored 82 49 104 63 105 61 291 58
 PR 19 11 10 6 14 8 43 8
Therapy shift 9 5 4 2 7 4 20 4
Maintenance 3 2 5 3 2 1 10 2
Relapse from CR/PR 55 33 40 24 38 22 133 26
Death in CR/PR — — 2 1 5 3 7 1
Total 168 165 171 504
NOTE. Because of rounding, percentages may not total 100.
Abbreviation: CR, complete remission; PR, partial remission; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP, rituximab
plus cyclophosphamide, vincristine, and prednisone; R-FM, rituximab plus fludarabine and mitoxantrone; TTF, time to treatment failure.
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3B). In addition, an unplanned exploratory analysis to assess potential
relationship between FLIPI2 and treatment suggested the highest ben-
efit with R-CHOP and R-FM over R-CVP in the larger group of
patients at intermediate risk (FLIPI2, 1 to 2; data not shown).
DISCUSSION
The results of the FOLL05 randomized study clearly demonstrated
that both R-CHOP and R-FM chemotherapy regimens lead to signif-
icantly improved TTF and PFS compared with R-CVP in patients with
previously untreated FL. However, R-FM was associated with higher
incidence of hematologic toxicity and late events compared with
R-CHOP and R-CVP. Moreover, the 3-year OS rate of 95% (95% CI,
92% to 97%) reinforces the assumption that end points such as TTF
and PFS are more realistic than OS for clinical trials involving patients
with FL.24
When the study started in 2006, data from randomized trials
confirmed that R added to any kind of chemotherapy improved treat-
ment results.3-5,25 The FOLL05 study was designed to compare the
three most commonly adopted regimens to define which one should
be used as the treatment of choice: R-CHOP, R-CVP, and R-FM.
Before the FOLL05 trial, almost all studies investigating the role of
anthracyclines in FL were based on retrospective series and/or in-
cluded patients with FL and other low-grade lymphomas.6,26,27 More-
over, results obtained with chemotherapy in the pre-R era needed to
be reassessed under the conditions of highly effective ICT combina-
tions. The main findings of the FOLL05 study were that chemotherapy
choice still affects treatment results in the R era and that the addition of
doxorubicin to CVP is required to improve efficacy of initial therapy.
As shown in the post hoc analysis of TTF and PFS, the benefit of
anthracycline was evident in almost all subgroups, except in those at
high risk according to FLIPI. However, this latter finding that seem-
ingly contrasts with current expectations and with recent data28 may
have resulted from the small number of patients in the high-risk
group, which did not translate the risk ratios of 0.63 and 0.79 observed
for TTF and PFS, respectively, into statistically significance. Interest-
ingly, compared with R-CVP, R-CHOP was not associated with
higher risk of cardiac toxicity, which was reported at a low rate across
the study.
Our results were compared with similar studies: the R-CVP arm
of the randomized trial by Marcus et al25 and the R-CHOP arm of the
German Low-Grade Lymphoma Study Group (GLGSG) randomized
study.3 All studies included similar populations of adult patients with
advanced FL. R-CVP treatment modalities were also the same, and
both ORR and PFS were superimposable, suggesting that the R-CVP
arm used in our study has highly reproducible results and worked at its
best. R-CHOP ORR was similar to that published in the GLGSG study,
whereas PFS was lower in our trial because of the adoption of both
postinduction therapies with interferon and high-dose therapies in
responding patients in the GLGSG trial.
When the study was designed, fludarabine was quoted in the
literature as an effective drug for FL treatment, either alone or in
combination.29,30 Additionally, FM was compared with CHOP in a
phase III trial and was proposed as a more effective chemotherapy for
first-line treatment of FL in terms of both clinical and molecular
responses.30 On the basis of these results, it seemed to us appropriate
to assess the efficacy of a fludarabine-containing regimen with con-
comitant R. The FOLL05 study concludes that both CHOP and FM
with concomitant R have the same antilymphoma profile and are both
superior to R-CVP in terms of TTF and PFS. These results compare
favorably with those achieved in other phase II trials investigating R
with fludarabine-based regimens.8-10,31 The FOLL05 study, however,
suggests that fludarabine-based regimens have a lower therapeutic
index than R-CHOP because of the higher frequency of adverse
events, mainly hematologic, and, most importantly, the higher ob-
served number of second malignancies. Among the 171 patients ran-
domly assigned to receive R-FM, 14 developed a second malignancy,
suggesting a higher risk for second cancer associated with fludarabine-
containing regimens, as already described in some retrospective re-
ports on indolent lymphoma.32
At time of current analysis, with median follow-up of 34 months,
the observed 95% OS rate confirms the excellent results achieved with
ICT in patients with FL.3,4,25,33 No further analysis was performed, and















































126 2418 3630 42 605448
B
No. at risk
R-CVP 168 136 119 95 74 51 36 23 13 5 1
R-CHOP 165 147 137 120 83 66 47 32 19 12 5
R-FM 171 150 139 120 95 68 50 32 20 12 4
No. at risk
R-CVP 168 154 136 108 85 60 41 27 14 6 1
R-CHOP 165 157 147 128 89 70 51 36 22 14 6
R-FM 171 163 151 130 101 73 55 36 23 14 5
Fig 2. Kaplan-Meier analysis of probability of (A) time to treatment failure and (B)
progression-free survival according to intention-to-treat principle. R-CHOP, ritux-
imab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CVP,
rituximab plus cyclophosphamide, vincristine, and prednisone; R-FM, rituximab
plus fludarabine and mitoxantrone.
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power caused by the low number of events (n  31) would have
distorted any kind of result.
Recently, the PRIMA (Primary Rituximab and Maintenance)
trial concluded that 2-year maintenance with R is to be considered
standard therapy for patients responding to initial ICT.34 However, at
the time of our study design, consensus regarding the role of mainte-
nance had not been established. As a result, no maintenance was
administered at end of therapy in our study.
Interestingly, 3-year PFS of the 458 responding patients in the
FOLL05 study completely overlaps that of the 513 patients randomly
assigned to the observation arm of the PRIMA study. PFS in the
FOLL05 population validates the findings of the PRIMA study, ulti-
mately confirming the benefit of 2 years of R maintenance after
achievement of satisfactory response with ICT. Considering results
from both the FOLL05 study and the PRIMA trial, we conclude that
the current standard therapy for patients with advanced FL should be
R-CHOP followed by 2-year maintenance therapy with R for re-
sponding patients.
Recently bendamustine and lenalidomide were suggested as ef-
fective drugs for patients with FL.33,35,36 In particular, in a randomized
trial conducted by STIL (Study Group Indolent Lymphomas),
R-bendamustine (R-B) was compared with R-CHOP in a group of
indolent and mantle-cell lymphomas. The study demonstrated
that all patients, as well as the FL subgroup, treated with R-B had
similar response rates compared with those achieved with
R-CHOP, with improved PFS and toxicity profile.33 Thus, R-B may
prove to be a valid alternative to R-CHOP as a standard initial





IC %59 RH liaF n elbairaV
 
Age, years
69.0 ot 34.0 46.0 79 422 06 <  
79.0 ot 13.0 55.0 05 901 06 >  
 
Hb
78.0 ot 24.0 16.0 021 082 21 >  
82.1 ot 82.0 06.0 72 35 21 <  
 
LoDLIN
40.1 ot 84.0 17.0 401 052 6 <  
08.0 ot 22.0 24.0 34 38 6 >  
 
B2M
59.0 ot 83.0 06.0 57 091 LNU <  
69.0 ot 83.0 06.0 27 341 LNU >  
 
BM
21.1 ot 83.0 56.0 55 951 -  
68.0 ot 83.0 75.0 29 471 +  
 
FLIPI
49.0 ot 93.0 16.0 38 112 2-0  





IC %59 RH liaF n elbairaV
 
Age, years
00.1 ot 14.0 46.0 18 422 06 <  
60.1 ot 23.0 85.0 54 901 06 >  
 
Hb
09.0 ot 14.0 16.0 401 082 21 >  
94.1 ot 82.0 46.0 22 35 21 <  
 
LoDLIN
49.0 ot 14.0 26.0 19 052 6 <  
82.1 ot 33.0 56.0 53 38 6 >  
 
B2M
61.1 ot 44.0 17.0 66 091 LNU <  
68.0 ot 13.0 15.0 06 341 LNU >  
 
BM
22.1 ot 83.0 86.0 74 951 -  
09.0 ot 73.0 85.0 97 471 +  
 
FLIPI
78.0 ot 43.0 45.0 07 112 2-0  
43.1 ot 74.0 97.0 65 221 5-3  
Fig 3. Post hoc exploratory analysis us-
ing Cox proportional hazards regression
models of (A) time to treatment failure and
(B) progression-free survival among patients
assigned to receive rituximab plus cyclophos-
phamide, doxorubicin, vincristine, and predni-
sone (R-CHOP) versus rituximab plus
cyclophosphamide, vincristine, and predni-
sone (R-CVP). B2M, 2-microglobulin; BM,
bone marrow; FLIPI, Follicular Lymphoma In-
ternational Prognostic Index; Hb, hemoglobin;
HR, hazard ratio; LoDLIN, longest diameter of
largest involved node.
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In conclusion, the FOLL05 trial supports R-CHOP as the refer-
ence regimen for initial management of patients with FL requiring
active treatment. However, new questions have already arisen regard-
ing both the efficacy of new promising drugs and best patient manage-
ment at end of induction therapy. Available data suggest that
quantitative assessment of response measured with either highly sen-
sitive polymerase chain reaction–based arrays37 or, more recently,
new functional imaging tools [18F]fluorodeoxyglucose–positron
emission tomography38-40 may be used to identify patients at different
risks of progression, for whom different maintenance strategies
are necessary.
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ERRATUM
The April 20, 2013, article by Federico, et al entitled, “R-
CVP Versus R-CHOP Versus R-FM for the Initial Treatment of
Patients With Advanced-Stage Follicular Lymphoma: Results
of the FOLL05 Trial Conducted by the Fondazione Italiana
Linfomi” (J Clin Oncol 31:1506-1513, 2013), contained errors.
In Table 1, a footnote gave the maximum dose of vincris-
tine as “Maximum of 2 mg/m2,” whereas it should have read,
“Capped at a total dose of 2 mg.”
Also, in the Patients and Methods section, under Statistics
and Assessment of Efficacy, the second sentence of the third
paragraph gave the final accrual as 531, whereas it should have
been 534, as follows: “After enrollment of the first 214 patients,
because actual accrual was faster than expected, the study was
amended as follows: 4 years of uniform recruitment, 1 year of
follow-up from last enrolled patient, and final accrual of 534
patients (178 patients per study arm).”
The online version has been corrected in departure from
the print.
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